Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 1, 2011, Pages 38-45

  Hellwinkel, O J C ^a   Asong, L E ^a   Rogmann, J P ^a   Sultmann H ^b   Wagner, C ^a   Schlomm, T ^a   Eichelberg, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

E3 ubiquitin ligase; prostate carcinoma; proteasome; transcription; tumour marker

Indexed keywords

PROTEASOME; PROTEASOME 26S SUBUNIT ADENOSINE TRIPHOSPHATASE 4; PROTEASOME SUBUNIT BETA TYPE 5; PROTEINASE; SMAD SPECIFIC E3 UBIQUITIN PROTEIN LIGASE 2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UBIQUITIN PROTEIN LIGASE NEDD4L; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; CARCINOMA; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 79951677186     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.48     Document Type: Article

References (35)

1. Schwab M. Ubiquitin. In: Schwab M, (eds). Encyclopedic Reference of Cancer. Berlin, Heidelberg, New York: Springer, 2001. p 937-943.
2. Zwickl P, Baumeister W. The Proteasome-Ubiquitin Protein Degradation Pathway. Berlin, Heidelberg, New York: Springer, 2002.
3. Cooper GM. Protein degradation. In: ASM Press Washington DC, (eds). The Cell, A Molecular Approach, 2. ed. Sunderland Massechusetts: Sinauer Associates Inc, 2000; p. 305-309.
4. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789. (Pubitemid 46224082)
5. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004; 40: 2217-2229. (Pubitemid 39348871)
6. Devoy A, Soane T, Welchman R, Mayer RJ. The ubiquitinproteasome system and cancer. Essays Biochem 2005; 41: 187-203.
7. Hellwinkel OJ, Rogmann JP, Asong LE, Luebke AM, Eichelberg C, Ahyai S et al. A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU Int 2008; 101: 1454-1460. (Pubitemid 351623985)
8. Schlomm T, Luebke AM, Sultmann H, Hellwinkel OJ, Sauer U, Poustka A et al. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol 2005; 27: 713-720.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
10. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479. (Pubitemid 28411135)
11. Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 2004; 1695: 55-72. (Pubitemid 39585154)
12. Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T et al. Overexpression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 2007; 104: 21-30. (Pubitemid 46976634)
13. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316-6325. (Pubitemid 38031815)
14. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977-2981. (Pubitemid 41565888)
15. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498. (Pubitemid 41007864)
16. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007; 13: 1208-1215. (Pubitemid 46424062)
17. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007; 13 (18 Part 1): 5291-5294. (Pubitemid 47510352)
18. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E et al. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res 2010; 16: 348-357.
19. Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res 2007; 13: 3642-3651. (Pubitemid 46955128)
20. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGFbeta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 2005; 386 (Part 3): 461-470. (Pubitemid 40445870)
21. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT et al. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999; 39: 285-290. (Pubitemid 29244503)
22. Wikstrom P, Bergh A, Damber JE. Transforming growth factorbeta1 and prostate cancer. Scand J Urol Nephrol 2000; 34: 85-94. (Pubitemid 32046846)
23. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signalling pathways. Oncogene 2003; 22: 4314-4332. (Pubitemid 36897963)
24. Yang J, Wahdan-Alaswad R, Danielpour D. Critical role of Smad2 in tumor suppression and transforming growth factorbeta-induced apoptosis of prostate epithelial cells. Cancer Res 2009; 69: 2185-2190.
25. Qi H, Grenier J, Fournier A, Labrie C. Androgens differentially regulate the expression of NEDD4L transcripts in LNCaP human prostate cancer cells. Mol Cell Endocrinol 2003; 210: 51-62. (Pubitemid 37386317)
26. Hu XY, Xu YM, Fu Q, Yu JJ, Huang J. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. Eur J Surg Oncol 2009; 35: 527-531.
27. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009; 69: 1470-1479.
28. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 2000; 275: 36818-36822. (Pubitemid 32002092)
29. Fukuchi M, Fukai Y, Masuda N, Miyazaki T, Nakajima M, Sohda M et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res 2002; 62: 7162-7165. (Pubitemid 36025230)
30. Chen C, Matesic LE. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 2007; 26: 587-604. (Pubitemid 350119775)
31. Fukunaga E, Inoue Y, Komiya S, Horiguchi K, Goto K, Saitoh M et al. Smurf2 induces ubiquitin-dependent degradation of Smurf1 to prevent migration of breast cancer cells. J Biol Chem 2008; 283: 35660-35667.
32. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M et al. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009; 284: 6109-6115.
33. Jin C, Yang YA, Anver MR, Morris N, Wang X, Zhang YE. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res 2009; 69: 735-740.
34. Kaminska B, Wesolowska A, Danilkiewicz M. TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005; 52: 329-337. (Pubitemid 41133768)
35. Perttu MC, Martikainen PM, Huhtala HS, Blauer M, Tammela TL, Tuohimaa PJ et al. Altered levels of Smad2 and Smad4 are associated with human prostate carcinogenesis. Prostate Cancer Prostatic Dis 2006; 9: 185-189. (Pubitemid 43970969)